Science News
from research organizations

Epigenetic treatments: New allies for chemotherapies?

April 11, 2022
Though chemotherapies are effective in some patients, tumour cells may acquire tolerance to these treatments. In other words, cells adapt to chemotherapy so they can survive. A new study delivers promising results on epigenetic mechanisms that regulate gene expression.


If genetics is interested in gene sequencing, epigenetics studies how genes are going to be used, or not used, by a cell. The epigenome of a cell represents the set of chemical modifications of the DNA or associated proteins that will determine the expression of the genes and thus the cell's identity. This information, which is central from the development of the embryo onwards, leads to changes in how our genes are expressed without affecting their sequence. By modifying its epigenome, the cell can adapt quickly to its environment. Genetics and epigenetics work together to enable cells to perform their function.

A research team1 led by Celine Vallot, CNRS Research Director in the Laboratoire Dynamique de l'information Génétique: Bases Fondamentales et Cancer (CNRS/Institut Curie/Sorbonne Université), and the Département de Recherche Translationnelle de l'Institut Curie (CNRS/Institut Curie/Sorbonne University), analysed cell by cell the epigenetic variations acquired by tumour cells during chemotherapy treatment. In collaboration with the team of Léila Périé, a CNRS researcher at the Physico-chimie Curie (CNRS/Institut Curie/Sorbonne Université), the scientists identified the genes whose expression allowed cells to tolerate2 treatment, as well as the epigenomic modifications that regulate them. Scientists have found that epigenomic marks "lock" the expression of these genes in the absence of treatment, and that this lock jumps under chemotherapy in rare cells. If this lock is prevented from jumping, all cancer cells remain sensitive to treatment. Scientists have demonstrated this by using chemical compounds called epi-drugs3 on animal models of breast cancer that inhibit the removal of epigenetic marks. These molecules still need to be adapted for human use.

These results clearly demonstrate the epigenome's involvement in resistance to cancer treatment. The scientists are now actively seeking how to apply this concept to humans from a therapeutic perspective. If future clinical trials are convincing, scientists imagine that these epi-treatments could be used in conjunction with chemotherapies to prolong their effectiveness in patients.


Story Source:

Materials provided by CNRS. Note: Content may be edited for style and length.

Journal Reference:

  1. Justine Marsolier, Pacôme Prompsy, Adeline Durand, Anne-Marie Lyne, Camille Landragin, Amandine Trouchet, Sabrina Tenreira Bento, Almut Eisele, Sophie Foulon, Léa Baudre, Kevin Grosselin, Mylène Bohec, Sylvain Baulande, Ahmed Dahmani, Laura Sourd, Eric Letouzé, Anne-Vincent Salomon, Elisabetta Marangoni, Leïla Perié, Céline Vallot. H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nature Genetics, 2022; 54 (4): 459 DOI: 10.1038/s41588-022-01047-6

Cite This Page:

CNRS. "Epigenetic treatments: New allies for chemotherapies?." ScienceDaily. ScienceDaily, 11 April 2022. <>.
CNRS. (2022, April 11). Epigenetic treatments: New allies for chemotherapies?. ScienceDaily. Retrieved October 2, 2023 from
CNRS. "Epigenetic treatments: New allies for chemotherapies?." ScienceDaily. (accessed October 2, 2023).

Explore More
from ScienceDaily